Amoy Diagnostics (300685.SZ) stock price, revenue, and financials

Amoy Diagnostics market cap is ¥16.8 b, and annual revenue was ¥578.36 m in FY 2019

¥16.8 B

300685.SZ Mkt cap, 10-Nov-2021

¥283 M

Amoy Diagnostics Revenue H1, 2020
Amoy Diagnostics Gross profit (H1, 2020)249.4 M
Amoy Diagnostics Gross profit margin (H1, 2020), %88.1%
Amoy Diagnostics Net income (H1, 2020)80.8 M
Amoy Diagnostics EBIT (H1, 2020)93.3 M
Amoy Diagnostics Cash, 30-Jun-2020362.4 M
Amoy Diagnostics EV16.5 B
Get notified regarding key financial metrics and revenue changes at Amoy DiagnosticsLearn more
Banner background

Amoy Diagnostics Revenue

Amoy Diagnostics revenue was ¥578.36 m in FY, 2019 which is a 31.7% year over year increase from the previous period.

Embed Graph

Amoy Diagnostics Revenue Breakdown

Embed Graph

Amoy Diagnostics revenue breakdown by business segment: 13.9% from Testing Services, 82.7% from Pharmaceutical Manufacturing and 3.4% from Other

Amoy Diagnostics revenue breakdown by geographic segment: 11.3% from Foreign and 88.7% from Domestic

Amoy Diagnostics Income Statement

Annual

CNYFY, 2017FY, 2018FY, 2019

Revenue

330.4m439.0m578.4m

Revenue growth, %

33%32%

Cost of goods sold

25.2m39.4m55.7m

Gross profit

305.1m399.7m522.6m

Gross profit Margin, %

92%91%90%

Sales and marketing expense

129.8m171.9m220.3m

R&D expense

50.8m78.3m93.8m

General and administrative expense

25.9m25.8m70.4m

Operating expense total

206.5m276.0m384.4m

EBIT

106.4m143.9m162.5m

EBIT margin, %

32%33%28%

Interest expense

257.9k605.8k50.3k

Interest income

1.3m2.6m13.2m

Investment income

1.2m5.6m(5.8m)

Pre tax profit

106.9m142.4m161.3m

Income tax expense

12.9m15.6m25.9m

Net Income

94.1m126.7m135.5m

EPS

1.40.90.9

Half Year

CNYH1, 2018H1, 2019H1, 2020

Revenue

202.5m265.9m283.0m

Cost of goods sold

16.3m25.0m33.6m

Gross profit

186.2m240.9m249.4m

Gross profit Margin, %

92%91%88%

Sales and marketing expense

72.6m100.7m71.4m

R&D expense

32.9m40.5m52.9m

General and administrative expense

12.4m24.5m50.8m

Operating expense total

117.9m165.7m175.1m

EBIT

79.9m88.5m93.3m

EBIT margin, %

39%33%33%

Interest expense

4.8k48.5k511.0k

Interest income

1.3m2.5m4.3m

Investment income

3.4m1.4m(2.0m)

Pre tax profit

79.8m88.5m92.7m

Income tax expense

10.2m10.4m11.9m

Net Income

69.6m78.2m80.8m

EPS

0.50.50.4

Amoy Diagnostics Balance Sheet

Annual

CNYFY, 2017FY, 2018FY, 2019

Cash

167.8m198.2m498.4m

Accounts Receivable

141.0m188.9m233.1m

Prepaid Expenses

678.6k1.1m14.2m

Current Assets

509.4m564.9m797.4m

PP&E

129.9m144.2m143.9m

Total Assets

694.8m818.7m1.0b

Accounts Payable

9.6m13.0m16.5m

Short-term debt

2.0m11.7m5.0m

Current Liabilities

39.1m56.6m140.6m

Non-Current Liabilities

6.5m5.4m4.1m

Total Debt

2.0m11.7m5.0m

Total Liabilities

45.6m62.0m144.7m

Common Stock

80.0m144.0m147.2m

Additional Paid-in Capital

396.9m332.9m437.0m

Retained Earnings

155.5m250.8m347.3m

Total Equity

649.2m756.7m902.1m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.1 x1.1 x1.2 x

Half Year

CNYH1, 2018H1, 2019H1, 2020

Cash

193.9m252.9m362.4m

Accounts Receivable

165.8m213.3m265.0m

Prepaid Expenses

3.2m4.0m2.0m

Current Assets

570.4m705.8m947.9m

PP&E

133.4m142.9m143.8m

Total Assets

759.7m950.2m1.2b

Accounts Payable

9.2m13.5m27.1m

Short-term debt

10.0m44.8m

Current Liabilities

54.8m127.8m187.0m

Non-Current Liabilities

5.3m4.5m7.4m

Total Debt

10.0m44.8m

Total Liabilities

60.2m132.2m194.4m

Common Stock

144.0m147.2m221.9m

Additional Paid-in Capital

332.9m411.0m417.8m

Retained Earnings

205.9m302.5m391.1m

Total Equity

699.6m818.0m1.0b

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.1 x1.2 x1.2 x

Amoy Diagnostics Cash Flow

Annual

CNYFY, 2017FY, 2018FY, 2019

Net Income

94.1m126.7m135.5m

Depreciation and Amortization

16.4m19.7m24.2m

Accounts Receivable

(30.8m)(51.8m)(62.3m)

Inventories

(1.0m)(4.4m)(3.1m)

Accounts Payable

6.6m7.0m54.1m

Cash From Operating Activities

91.9m93.4m151.5m

Purchases of PP&E

(21.7m)(39.0m)(23.3m)

Cash From Investing Activities

(240.6m)(56.3m)108.0m

Short-term Borrowings

(10.0m)(30.9m)(11.7m)

Dividends Paid

(412.8k)(19.8m)(26.5m)

Cash From Financing Activities

238.8m(10.1m)38.4m

Net Change in Cash

85.6m30.4m300.2m

Half Year

CNYH1, 2018H1, 2019H1, 2020

Net Income

69.6m78.2m80.8m

Depreciation and Amortization

9.4m11.8m13.1m

Accounts Receivable

(29.3m)(28.7m)(22.9m)

Inventories

(64.6k)(3.3m)(25.9m)

Accounts Payable

8.0m23.6m47.4m

Cash From Operating Activities

54.9m81.6m89.3m

Purchases of PP&E

(15.3m)(9.1m)(19.5m)

Cash From Investing Activities

(18.9m)(61.2m)(257.7m)

Short-term Borrowings

(2.0m)(11.7m)(5.0m)

Dividends Paid

(19.3m)(26.5m)(37.2m)

Cash From Financing Activities

(11.3m)33.7m30.1m

Net Change in Cash

26.1m54.6m(136.0m)

Amoy Diagnostics Ratios

CNYFY, 2017

Revenue/Employee

796.1k

Financial Leverage

1.1 x

Amoy Diagnostics Operating Metrics

FY, 2017H1, 2018FY, 2018H1, 2019FY, 2019H1, 2020

Medical Institutions Covered

300300400400500500

Medical Device Registration Certificates

181921222222

Patents (Domestic)

212429283234

Patents (Foreign)

333

Amoy Diagnostics Human Capital

Job Roles

FY, 2019FY, 2018FY, 2017
Administration14.2%14%11.8%
Technical and Engineering34.9%36.6%35.4%
Sales and Marketing39.9%37.3%40.5%
Production9.2%10.2%10.1%
Other1.8%1.8%2.2%